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.2013.02.Abstract Aim: To compare the efﬁcacy of intramuscular ketamine, dexmedetomidine, and a mix-
ture of both for pediatric MRI sedation.
Subjects and methods: One-hundred and sixty-two children with ASA physical I–II were enrolled in
a double-blind comparative study and assigned into three equal groups for sedation. Group D,
patients received IM dexmedetomidine 3 lg/kg. Group K, patients received IM ketamine 4 mg/
kg. Group DK, patients received a combination of IM dexmedetomidine 1.5 lg/kg and ketamine
2 mg/kg. Primary outcomes included incidence of failed sedation and the requirement of midazolam
supplementation. Secondary outcomes were time to sedation, duration of sedation, and discharge
time.
Results: The onset of satisfactory sedation was signiﬁcantly shorter in the DK group in comparison
with the D group (4.8 ± 1.6 vs. 16.8 ± 4.5 min), while no signiﬁcant difference between the DK
group and K group. The duration of sedation was signiﬁcantly less in the DK group in comparison
with the K group, and the discharge time was signiﬁcantly less in the DK group in comparison with
the D and K groups. The sedation failure rate was signiﬁcantly lower in the DK group (5.6%) in
comparison with the K group (22.2%) and the D group (27.8%). The use of rescue midazolam
was signiﬁcantly less in the DK group (0.03 ± 0.12 mg) in comparison with the K and D groups
(0.21 ± 0.41 mg, 0.24 ± 0.41 mg, respectively). None of the patients experienced episodes of hypo-
tension or bradycardia in the DK and K groups while four patients (7.4%) experienced episodes of
hypotension and ﬁve patients (9.3%) experienced episodes of bradycardia in the D group.nd Intensive Care, The Suez
gypt. Tel.: +20 1099122663.
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242 T.F. TammamConclusion: In pediatric MRI sedation, the combination of IM dexmedetomidine and ketamine
was superior to either IM dexmedetomidine or ketamine given individually with regard to the onset
of sedation, the sedation failure rate, and hemodynamic stability.
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MRI scanning poses a challenge to the anesthesiologists in
providing adequate sedation without compromising the pa-
tient’s airway or hemodynamics and ensuring rapid recovery.
The additional safety challenges posed by remote locations
make the highest level of vigilance essential during MRI study
when planning and performing sedation for children [1]. Dex-
medetomidine has been associated with rapid onset and offset
and a natural, sleep-like state [2], but patients receiving dex-
medetomidine have been observed to be easily aroused by min-
imal stimulants, such as MRI noise. Movement was noted to
be a problem by using dexmedetomidine that leads to MRI
rescanning [3]. The adverse effects of alpha-2 agonist are
dose-dependent [4,5]. Bradycardia and hypotension are the
most reported side effects of IV dexmedetomidine [4,6–8].
The experience of concurrent use of Intramuscular (IM) dex-
medetomidine with other agents in pediatric sedation is lack-
ing. It is potential to administer the dexmedetomidine in
conjunction with other agents [9] to avoid the adverse effects
of dexmedetomidine. The individual disadvantages of dex-
medetomidine and ketamine can be counterbalanced when
used in combination [10]. The aim of the study was to compare
the efﬁcacy of intramuscular dexmedetomidine, ketamine, and
a mixture of both for pediatric MRI sedation.
2. Patients and methods
One-hundred and sixty-two patients between the ages of 2–
7 years with ASA physical status I–II, planned for elective
MRI were enrolled in a double-blind comparative study, after
obtaining approval of the hospital’s Research Ethics Commit-
tee and written informed consent from parents to the study.
The study was carried out from March 2010 to April 2012. Pa-
tients with a history of active upper or lower respiratory tract
disease, renal or hepatic diseases, cardiovascular disease, and
current use of digoxin or beta blockers were excluded. Patients
with increased intracranial pressure, previous adverse reaction
to ketamine or by reason of parents’ refusal were also excluded
from the study. Sample size was calculated using EPI-INFO
program. The incidence of sedation failure was the primary
endpoint of the study. The alpha-error level was ﬁxed at 0.05
and power was set at 80% while the expected change to be de-
tected was 10%. The required study size was 54 patients per
group. Patient demographic data, patient’s ASA physical sta-
tus, type of MRI study performed, and its imaging time were
recorded. Patients were randomized to one of three groups:
Group D (n= 54) where sedation was carried out using IM
dexmedetomidine hydrochloride (Precedex, Abbott) 3 lg/
kg; Group K (n= 54) where patients received IM ketamine
[11] (Hikma pharmaceutical Jordan) 4 mg/kg; and Group
DK (n= 54) where patients received single IM dexmedetomi-
dine and ketamine, half the doses mentioned above for both
drugs (1.5 lg/kg and 2 mg/kg, respectively). Parents wereinstructed to make their children NPO for solids 6 hours (h)
prior to their scheduled appointment and to give clear liquids
up to 2 h prior to the procedure. Before the procedure, EMLA
cream was applied 1 h to the places of intravenous (IV) cannu-
lation and IM injection. Monitoring of electrocardiogram
(ECG), peripheral oxygen saturation (SPO2), and non-invasive
blood pressure (NIBP) was established before the procedure.
Rhythm and heart rate (HR) were displayed by using a lead
II ECG. All sedatives were mixed with 0.9% saline in a syringe
to a total volume of 1.5 ml by a nurse, and then, the injection
was administered by blinded anesthetists to the medication.
The selected sedative was given as a single IM injection in
the lateral upper thigh muscle using a 25 gauge needle. Ran-
domization was performed by means of a computer generated
random-numbers table. The patients were randomly assigned
on one-to-one ratio. Sedation levels were consecutively as-
sessed with Ramsay sedation score (RSS). Primary outcomes
included the incidence of failed sedation and the requirement
of midazolam supplementation. Secondary outcomes were
time to sedation, duration of sedation, and discharge time.
Incidence of adverse events was noted.
The following data were collected by anesthesiologists
blinded to the group assignment. All variables of vital signs
(measured MBP, HR, SPO2, and RR) were recorded at base-
line, pre-sedation, 5-min intervals throughout the procedure
and every 10 min post-sedation in the recovery room. Imaging
time referred to the duration of imaging study from initiation of
scan till the radiologist conﬁrms completion of successful MRI
study. The time to sedation is deﬁned as the time in minutes
(min) from administration of sedative to achievement of
adequate sedation (RSS 4) of the patient. Duration of sedation
is deﬁned as the time from onset of sedation to offset of sedation
(RSS 2). Time to discharge is the time from giving sedation to
point at which patient attained the discharge criteria (Alderete
score of 8 or greater) [12]. A failed sedation refers to inadequate
sedation (RSS less than 4) or inability to complete the planned
procedure secondary to unacceptable motion artifacts.
The sedation was classiﬁed as failed if the sedation was
deemed inadequate after 30 min, and supplemental sedation
was provided by using titrated doses of IV midazolam
0.05 mg/kg every 4 min up to 0.4 mg/kg). Incidence of compli-
cations during and after the procedure was documented by the
anesthetists. Hypotension and bradycardia were deﬁned as
deviation of greater than 20% below the child’s baseline. Oxy-
gen desaturations less than 92%, airway complications, emer-
gence phenomena, vomiting, and unplanned admission were
recorded. The radiologist evaluated their satisfaction of seda-
tion ‘‘quality of MRI and continuity of MRI procedure’’,
using a 10-cm Visual Analog Scale (VAS) score (0, sedation
unsatisfactory and 10, sedation very satisfactory).
Statistical analyses: Data were analyzed using the IBM
computer using SPSS version 12. The data are presented as
means ± standard deviation (SD) for continuous variables
and as counts and percentages for nominal data. The one
Pediatrics sedation for imaging study 243way ANOVA test for independent means, or Pearson’s chi-
square test where appropriate was used to identify differences
between the groups. A probability value of less than 0.05 was
considered statistically signiﬁcant.
3. Results
There was no statistical signiﬁcant difference between the
groups with respect to patient’s characteristics, type, and dura-
tion of the imaging studies (p> 0.05; Tables 1 and 2). The on-
set of satisfactory sedation was signiﬁcantly shorter in the DK
group in comparison with the D group (4.8 ± 1.6 min vs.
16.8 ± 4.5 min), while no signiﬁcant difference between the
DK group and K group (Table 3). The duration of sedation
was signiﬁcantly less in the DK group in comparison with
the K group, and the discharge time was signiﬁcantly less in
the DK group in comparison with the D and K groups (Ta-
ble 3). Although all the patients successfully completed the
MRI studies, the sedation failure rate was signiﬁcantly lower
in the DK group (5.6%) in comparison with the K group
(22.2%) and the D group (27.8%), (Table 3). Also, the useTable 2 Distribution of the MRI studies in the three groups.
Type of examination Group D (n= 54) Group D
Head or neck 33 (61.1%) 33 (61.1
Spine 3 (5.6%) 6 (11.2%
Thorax 6 (11.2%) 3 (5.6%
Abdomen 9 (16.6%) 9 (16.6%
Extremity 3 (5.6%) 3 (5.6%
Table 3 Sedation clinical characteristics in the three groups.
Group parameter Group D (n= 54) Group DK
Onset of sedation 16.8 ± 4.5\ 4.8 ± 1.6\
Duration of sedation 25.8 ± 3.6 24.7 ± 3.1
Time to discharge 37.2 ± 5.3\ 29.9 ± 2.1
Sedation failure rate 15 (27.8%) 3 (5.6%)
Rescue midazolam 0.24 ± 0.41\ 0.03 ± 0.1
Radiologist satisfaction 7.44 ± 0.5 9.33 ± 0.5
Values are expressed as mean ± SD or absolute numbers.
\ p< 0.05: comparing DK group to D regarding the onset of sedation.
\ p< 0.05: comparing DK group to K group regarding duration of seda
\ p< 0.05: comparing DK group to D group regarding the discharge tim
# p< 0.05: comparing DK group to K group regarding the discharge tim
Table 1 Patient demographics and clinical characteristics.
Group parameter Group D (n= 54) Group D
Age (year) 3.78 ± 1.39 3.89 ± 1.
Weight (kg) 15.31 ± 2.70 16.17 ± 3
ASA I/II 19/35 22/32
F/M 28/26 27/27
Imaging time 24.0 ± 3.9 24.0 ± 3.
Values are expressed as mean ± SD or absolute numbers.
Abbreviation: Male, M; female, F.
NS = no signiﬁcant difference; p> 0.05.of rescue midazolam was signiﬁcantly less in the DK group
(0.03 ± 0.12 mg) in comparison with the K and D groups
(0.21 ± 0.41 mg, 0.24 ± 0.41 mg, respectively) (Table 3). The
radiologists were signiﬁcantly very satisﬁed in the DK group
regarding the quality of MRI and the continuity of MRI pro-
cedure, in comparison with the D and K groups, (Table 3). In
the 5th to 45th min intervals, patients in the DK group had sig-
niﬁcantly higher HR compared to patients in the D group
(p< 0.05) while they had signiﬁcantly lower HR compared
to the patients in K group (p< 0.05; Table 4). Also, in the
5th to 35th min intervals, patients in the DK group had signif-
icantly lower MBP compared to patients in the K group
(p< 0.05, Table 5). Although the MBP dropped more in the
D group compared with the DK group, the difference was sta-
tistically insigniﬁcant (p> 0.05, Table 5). During the imaging
procedure, none of the patients experienced episodes of hypo-
tension or bradycardia in the DK and K groups while four pa-
tients (7.4%) experienced episodes of hypotension and ﬁve
patients (9.3%) experienced episodes of bradycardia in the D
group (Table 6). On the other hand, the incidence of tachycar-
dia and hypertension was 22.2% and 12.96%, respectively, inK (n= 54) Group K (n= 54) Signiﬁcance
%) 30 (55.5%) NS
) 6 (11.2%) NS
) 6 (11.2%) NS
) 9 (11.2%) NS
) 3 (5.6%) NS
(n= 54) Group K (n= 54) Signiﬁcance p value
4.6 ± 1.5 0.010
\ 47.8 ± 4.5\ 0.030
\,# 54.9 ± 3.7# 0.030
12 (22.2%) 0.007
2\,# 0.21 ± 0.41\,# 0.002
8.17 ± 0.6 0.004
tion.
e and midazolam supplementation.
e and midazolam supplementation.
K (n= 54) Group K (n= 54) Signiﬁcance
49 3.83 ± 1.15 NS
.38 15.61 ± 3.04 NS
21/33 NS
27/27 NS
9 24.1 ± 3.6 NS
Table 4 Hemodynamic variables (HR) comparing the three groups.
Group intervals Group D (n= 54) Group DK (n= 54) Group K (n= 54) Signiﬁcance (p value)
Baseline 100.50 ± 3.76 99.39 ± 4.02 99.17 ± 2.20 NS
5 min 85.17 ± 2.94# 98.56 ± 3.36*# 104.28 ± 4.97* 0.034
10 min 82.89 ± 6.92# 97.72 ± 3.43*,# 110.44 ± 10.36* 0.026
15 min 83.44 ± 9.28# 97.17 ± 3.59*,# 111.61 ± 8.31* 0.029
20 min 85.83 ± 8.71# 97.39 ± 3.68*,# 112.33 ± 6.95* 0.027
25 min 88.00 ± 6.42# 98.17 ± 3.70*,# 109.61 ± 6.32* 0.033
35 min 89.83 ± 5.38# 99.50 ± 3.68*,# 104.06 ± 4.04* 0.038
45 min 93.89 ± 3.91# 99.17 ± 3.40# 101.33 ± 2.93 0.040
Values are expressed as mean ± SD (M± SD).
* p< 0.05: comparing DK group with K group at 5–35 min intervals.
# p< 0.05: comparing DK group with D group at 5–45 min intervals.
Table 5 Hemodynamic variables (MBP) comparing the three groups.
Group interval Group D (n= 54) Group DK (n= 54) Group K (n= 54) Signiﬁcance p value
Baseline 62.67 ± 4.92 62.72 ± 6.33 62.83 ± 4.85 NS
5 min 61.00 ± 4.22 59.67 ± 6.21# 65.83 ± 4.77# 0.024
10 min 57.50 ± 4.15 59.50 ± 6.52# 67.44 ± 4.77# 0.015
15 min 55.22 ± 6.85 59.61 ± 6.74# 67.83 ± 4.63# 0.018
20 min 56.67 ± 5.18 59.78 ± 6.17# 67.56 ± 5.00# 0.016
25 min 57.72 ± 5.26 59.44 ± 5.97# 67.06 ± 5.61# 0.020
35 min 58.89 ± 4.80 59.56 ± 6.09# 65.50 ± 4.49# 0.022
45 min 59.94 ± 4.94 59.61 ± 6.38 63.22 ± 4.48 NS
Values are expressed as mean ± SD (M± SD).
# p< 0.05: comparing DK group with K group at 5–35 min intervals.
Table 6 Incidence of adverse events and complications.
Group variable Group D
(n= 54)
Group DK
(n= 54)
Group K
(n= 54)
Bradycardia 5 (9.3%) 0 (0.0%) 0 (0.0%)
Tachycardia 0 (0.0%) 0 (0.0%) 12 (22.2%)
Hypotension 4 (7.4%) 0 (0.0%) 0 (0.0%)
Hypertension 0 (0.0%) 0 (0.0%) 7 (12.96%)
Oxygen desaturation 2 (3.7.%) 0 (0.0%) 6 (11.1%)
Vomiting 1 (1.85%) 3 (5.6%) 8 (14.8%)
Emergence phenomena 0 (0.0%) 1 (1.85%) 7 (12.96%)
244 T.F. Tammamthe K group, while there were none in the D and DK groups
(Table 6). Patients in the K group had signiﬁcantly higher inci-
dence of vomiting (14.8%) and emergence phenomena
(12.96%), compared to the D and DK groups (Table 6). The
incidence of peripheral oxygen desaturation events was
11.1% in the K group, 3.7% in the D group and none in the
DK group (Table 6). Patients responded to head repositioning
and assisted oxygen mask ventilation. Oral airway placement
was required in two patients in the K group and one patient
in the D group. Oral suction for secretion was required in four
cases in the K group. None of the patients in the three groups
required hospital admission.
4. Discussion
Dexmedetomidine may be useful for pediatric sedation in a
variety of clinical situations [7]. The adverse events related to
its IV administration including bradycardia, hypotension,and easy arousability by minimal stimulants such as MRI
noise, presented a number of obstacles for successful sedation.
On using high dose dexmedetomidine as a sole sedative for
pediatric MRI, the cardiovascular side effects were noted in
16% of patients [13]. On the other hand, movement of children
was noted to be a problem on using low dose of dexmedetom-
idine and the addition of propofol was essential for rescanning
[3].
There are a limited number of studies regarding using the
IM dexmedetomidine, and the experience of concurrent use
of dexmedetomidine with other agents in pediatric sedation
is lacking. The IM dexmedetomidine administration could be
an alternative to the IV dexmedetomidine use for pediatric
sedation [14]; however, the IM administration has a late seda-
tion onset compared to the IV route [15]. The dexmedetomi-
dine given intramuscularly reduces the sedation failure rate,
the need for supplement sedation and the incidence of hemody-
namic instability associated with the IV administration [15].
The mixture of dexmedetomidine and midazolam showed ade-
quate sedation for MRI; however, the combination resulted in
more cases of prolonged recovery, bradycardia, and hypoten-
sion in pediatric patients [16]. Also, 12.5% of infants and chil-
dren who received IV ketamine and dexmedetomidine prior to
diagnostic or therapeutic cardiac catheterization, required an
earlier reduction in the infusion rate of dexmedetomidine to
1 lg/kg/h because of bradycardia and 18.5% of patients re-
quired a supplemental dose of ketamine [17]. The intramuscu-
lar mixture of dexmedetomidine and ketamine administration
might avoid the adverse effects associated with dexmedetomi-
dine and might reduce the need for titration, which is essential
for IV sedation [18].
Pediatrics sedation for imaging study 245In this study, the patients given the ketamine–dexmedetom-
idine regimen had less sedation failure rate and required fewer
rescue doses of midazolam compared with the patients given
ketamine or dexmedetomidine separately. Also, patients given
the ketamine–dexmedetomidine mixture required less time to
be successfully sedated compared to patients given dexmede-
tomidine and required less time to discharge compared to pa-
tients given ketamine. Administration of an alpha-2 agonist in
conjunction with ketamine as part of a balanced regimen
might have a synergistic effect. This leads to improved quality
of sedation [9] and reduced incidence of adverse events. A case
series described the use of intravenous dexmedetomidine with
ketamine for MRI in three mechanically ventilated children
with trisomy 21 and obstructive sleep apnea [19]. The regimen
was effective, achieving sedation to properly complete MRI,
without clinically signiﬁcant effects on hemodynamics or respi-
ratory rate [19]. Also, Murat et al. [10] compared the sedo-
analgesic effects of intravenous ketamine–dexmedetomidine
and ketamine–midazolam on dressing changes of adult burn
patients. They noted both combinations offered an effective
sedo-analgesia without causing any signiﬁcant side effect, but
the ketamine–dexmedetomidine regimen resulted in higher
sedation scores.
In this study, patients given the IM dexmedetomidine–
ketamine combination showed less adverse effects and high
radiologist satisfaction of sedation compared to the other
sedatives. Hypotension and bradycardia are the most reported
adverse effects of IV dexmedetomidine [4,6,8,9]. Dexmedetom-
idine has an alpha-2 agonist effect on the sympathetic ganglia
[5,20], and it produces dose-dependent decreases in blood
pressure and heart rate. Dexmedetomidine (2 lg/kg/h) use in
children undergoing computed tomography [21] led to higher
drop in blood pressure and heart rate compared with baseline.
In this study, the hemodynamic status was stable without clin-
ically signiﬁcant changes in the dexmedetomidine–ketamine
group; however, signiﬁcant drop in MAP and HR were noted
in the dexmedetomidine only group. The hemodynamic side ef-
fects of dexmedetomidine and ketamine are the opposite of
each other. The dexmedetomidine provides a counterbalance
to the sympathetic stimulation and attenuates the hyper-adren-
ergic state associated with ketamine [10,22]. The use of dex-
medetomidine as a premedication was noted to be effective
in attenuating the cardio-stimulatory and post-anesthetic delir-
ium effects of ketamine [23]. Oxygen desaturation, vomiting,
and emergence phenomena occurred more frequently in the
ketamine group as compared to the other groups. The charac-
teristics of ketamine and dexmedetomidine are different with
respect to these outcomes. Although ketamine is not a respira-
tory depressant and has the advantage of maintaining protec-
tive airway reﬂexes [24], Owens et al. reported that 2.9% of the
patients who received ketamine during sedation experienced
side effects such as desaturation [25].
On the other hand, dexmedetomidine does not have active
role on the respiratory system [25,26]. There were no signs of air-
way obstruction and hypoxemia attributed to dexmedetomidine
use [27]. Vomiting is common in patients receiving ketamine.
Green et al. reported the incidence of vomiting to be 3.5% in
those aged less than 5 years and 12.1% in those aged 5 years
or older [28]. The rate of emesis is dose related, and it was
7.0% when the total ketamine dose was 7 mg/kg or less and
11.1% when greater than 7 mg/kg [29]. On other side, nausea
and vomiting are rare side effects of dexmedetomidine [8,30],and in some studies, the use of dexmedetomidine has been shown
to decrease the antiemetic use [31].
IM dexmedetomidine given in combination with ketamine
might have broad applications for sedation in children. The
individual disadvantages of dexmedetomidine and ketamine
can be counterbalanced when used in combination [10].
Although the concurrent use of dexmedetomidine and keta-
mine might be useful regarding the quality of sedation, differ-
ent doses of intramuscular dexmedetomidine–ketamine
mixture need to be compared to determine the optimal regimen
for pediatric sedation.
5. Conclusion
In pediatric MRI sedation, the combination of IM dexmede-
tomidine and ketamine was superior to either IM dexmede-
tomidine or ketamine given individually with regard to the
onset of sedation, the sedation failure rate, and hemodynamic
stability.
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